[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100573188":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":13,"locations":19,"responsibleParty":37,"collaborators":39,"id":43,"slug":7,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":44,"sex":50,"minAge":51,"maxAge":7,"enrollmentInfo":52,"targetDuration":7,"studyType":55,"phases":7,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":22,"whyStopped":7,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"iOMEDICO AG","INDUSTRY",null,[9],{"name":10,"affiliation":11,"role":12},"Eyck von der Heyde, Dr.","Onkologische Schwerpunktpraxis","PRINCIPAL_INVESTIGATOR",[14],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Laura Serrer","CONTACT","+49 761 15242-0","rope@iomedico.com",[20],{"facility":21,"status":22,"city":23,"state":24,"zip":25,"country":26,"cosmosGeoPoint":27,"geoPoint":32,"contacts":33},"Onkologisches Studienzentrum Dr. med. Ingo Zander & Dr. med. Eyck von der Heyde","RECRUITING","Hanover","Lower Saxony","30161","Germany",{"type":28,"coordinates":29},"Point",[30,31],9.73322,52.37052,{"lat":31,"lon":30},[34],{"name":10,"role":16,"phone":35,"phoneExt":7,"email":36},"+49511311660","vdheyde@onkologie-am-raschplatz.de",{"type":38,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[40],{"name":41,"class":42},"AOP Orphan Pharmaceuticals Germany GmbH","UNKNOWN","100573188",false,"NCT06743035","Ropeginterferon Alfa-2b in Patients With Polycythemia Vera (PV) Without Symptomatic Splenomegaly","Ropeginterferon Alfa-2b in Patients With Polycythemia Vera (PV) Without Symptomatic Splenomegaly: A Prospective, Longitudinal, Multicenter, Observational Study in Germany","ROPE","Inclusion Criteria:\n\n* Age ≥18 years\n* Confirmed diagnosis of PV without symptomatic splenomegaly\n* Indication and decision for treatment with ropeginterferon alfa-2b in accordance with current SmPC\n* No prior treatment with ropeginterferon alfa-2b (Patients are allowed to be enrolled up to 6 weeks after their first dose of ropeginterferon alfa-2b but must still be on treatment at the time of enrollment.)\n* Dated signature of informed consent form\n* Participation in Patient-Reported Outcome (PRO) assessment in German language and completion of questionnaire at time of study enrollment\n* Other criteria according to current Summary of Product Characteristics\n\nExclusion Criteria:\n\n* Participation in an interventional clinical trial (except follow-up)\n* Other contraindications according to current Summary of Product Characteristics","ALL","18 Years",{"count":53,"type":54},200,"ESTIMATED","OBSERVATIONAL","The primary objective of this non interventional study is to evaluate symptom burden in adult patients with PV without symptomatic splenomegaly during treatment with ropeginterferon alfa-2b in a real-world setting. Further patient-relevant endpoints include effectiveness including complete hematologic response (CHR), event-free survival (EFS), safety and tolerability, treatment reality including dosing details as well as factors affecting treatment decision making.",[58],"Polycythemia Vera",[60,61,62,63],"Ropeginterferon alfa-2b","polycythemia vera","symptom burden","myeloproliferative neoplasm","2026-01-08",{"date":66,"type":67},"2026-01-09","ACTUAL",{"date":69,"type":67},"2024-12-03",{"date":71,"type":54},"2029-07",{"name":5,"class":6},1]